ライフサイエンスコーパス: toremifene

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ed with only 35% of the animals treated with toremifene.

2 acebo group, but not in animals treated with toremifene.

3 lutamide (an antiandrogen; 33 mg/kg/day), or toremifene (10 mg/kg/day).

4 Although toremifene 20 mg did not lower the PCa detection rate, m

5 ate cancer were randomly assigned to receive toremifene (80 mg/d) or placebo.

6 Denosumab and toremifene (a selective estrogen receptor modulator) hav

7 We evaluated the effects of toremifene, a selective estrogen-receptor modulator, on

8 The chemopreventive efficacy of toremifene, an antiestrogen, was evaluated in the transg

9 Unexpectedly, both toremifene and ibuprofen bind in a cavity between the at

10 ion complexes of GP with the anticancer drug toremifene and the painkiller ibuprofen.

11 ive estrogen receptor modulators, tamoxifen, toremifene, and raloxifene with estradiol when given ora

12 ase in the protein melting temperature after toremifene binding, while ibuprofen has only a marginal

13 oxifen and most mice (12 of 14) treated with toremifene, but in none of the vehicle-dosed controls, i

14 We evaluated the efficacy of toremifene citrate 20 mg in PCa prevention among men wit

15 biopsy were randomly assigned 1:1 to receive toremifene citrate 20 mg or placebo in a 3-year phase II

16 Although both flutamide and toremifene decreased tumor incidence compared with the p

17 ene group (6.6 mg/kg/day); (b) the high-dose toremifene group (33 mg/kg/day); and (c) the control pla

18 gregated into three groups: (a) the low-dose toremifene group (6.6 mg/kg/day); (b) the high-dose tore

19 group (n = 10), at week 21 in the high-dose toremifene group (n = 12), and at week 29 in the low-dos

20 oup (n = 12), and at week 29 in the low-dose toremifene group (n = 12).

21 group and decreased by 8.1% +/- 1.4% in the toremifene group (P = .001 for between group comparison)

22 group and decreased by 13.2% +/- 3.6% in the toremifene group (P = .003).

23 group and decreased by 8.2% +/- 2.5% in the toremifene group (P = .003).

24 group and increased by 0.5% +/- 2.2% in the toremifene group (P = .018).

25 nth 12 were compared between the placebo and toremifene groups.

26 to the paucity of long-term clinical data on toremifene, important unresolved questions remain, which

27 Toremifene is not likely to be used as second-line thera

28 en is hepatocarcinogenic in the rat, whereas toremifene is not.

29 Toremifene is structurally similar to tamoxifen, differi

30 0 men with biopsy-diagnosed HGPIN to receive toremifene or placebo for 3 years or until a diagnosis o

31 Because toremifene prevented prostate cancer in a milieu of elev

32 iestrogens include agents such as tamoxifen, toremifene, raloxifene, and fulvestrant.

33 drogen receptor expression, the mechanism of toremifene's chemopreventive activity may be through non

34 Toremifene significantly decreased total cholesterol, LD

35 n contrast, the dehalogenated TAM derivative toremifene (TOR) did not inhibit MM cell proliferation.

36 hronic administration of tamoxifen (TAM) and toremifene (TOR) on genetic damage related to carcinogen

37 nown to promote hepatocarcinoma in rats, but toremifene (TOR), a chlorinated TAM analogue, did not.

38 nhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letr

39 Moreover, toremifene-treated animals had prolonged survival compar

40 T antigen levels in the prostate of toremifene-treated animals were similar to those of plac

41 palpable tumors and died, whereas 60% of the toremifene-treated animals were tumor free.

42 ree testosterone levels were elevated in the toremifene-treated group.

43 Toremifene treatment did not affect androgen receptor le

44 enes differentially modified by tamoxifen or toremifene treatment, relative to the controls.

45 d tumor incidence compared with the placebo, toremifene was more effective than flutamide.

46 A new antiestrogen, toremifene, was approved recently for use in managing me

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。